Insights from Dr Chepke - Tardive Dyskinesia: How do we go so wrong?
Tardive Dyskinesia (TD) is a drug-induced movement disorder that continues to be prevalent in patients treated with atypical antipsychotics,1 but is often underrecognised and/or misdiagnosed.2–4
In this video, Dr Craig Chepke (University of North Carolina School of Medicine, NC, US) explains the essential part that early recognition plays in the management of TD, from attenuating physical symptoms to alleviating the often disabling impact on patients’ quality of life.2-6
Learn more from Dr Chepke on recognising and managing TD.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151–6.
Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: A video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2020;1–10.
Carbon M, Hiseg C-H, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. J Clin Psychiatry 2017;78:e264–e278.
Ward KM, Citrome L. Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther 2018;7:233–248.
Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: A prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol 2020;40:259–268.
Ascher-Svanum H, Zhu B, Faries D, et al. Tardive dyskinesia and the 3-year course of schizophrenia: Results from a large, prospective, naturalistic study. J Clin Psychiatry 2008;69:1580–1588.
